Chinese Premier Li Qiang, who delivered a keynote speech at the opening ceremony of CDF 2025, underscored China’s commitment ...

Based on the terms of the agreement, BridgeBio will receive a $30 million milestone payment upon approval in Japan, as well ...

Rybrevant (amivantamab-vmjw) and Lazcluze (lazertinib) combination therapy is projected to increase overall survival (OS) by ...

The latest data from Johnson and Johnson's Rybrevant and Lazcluze lung cancer combo was better than standard of care Tagrisso ...

The World Business Council for Sustainable Development (WBCSD), in collaboration with leading pharmaceutical companies and ...

One half of J&J’s treatment is Lazcluze, a pill that, like Astra’s Tagrisso, blocks a cancer-associated protein called EGFR.

1. AstraZeneca to invest $2.5 billion in new global strategic R&D centre, biotech agreements and manufacturing in Beijing.

Johnson & Johnson has produced the most convincing data to date that its combination of Rybrevant and Lazcluze could replace ...

CINCINNATI ( Cincinnati Business Courier) - A growing biotech and pharmaceuticals manufacturer that announced a large ...

AstraZeneca Plc‘s win over shareholders who challenged its $3 billion sale of biotech firm Viela Bio Inc. was affirmed Wednesday by the Delaware Supreme Court.

New study results presented at the European Lung Cancer Congress 2025, March 26 to 29, demonstrate the role of AstraZeneca’s (AZN) TAGRISSO, as ...